SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should First Trust Dow Jones Select MicroCap ETF (FDM) Be on Your Investing Radar?

Sezzle stock (SEZL) jumped 15.6% in aftermarket trading on Tuesday after the digital payments platform’s fourth-quarter earnings exceeded Wall Street’s expectations.According to FinChat data, the company posted an adjusted net income of $4.39 per share for the fourth quarter, while analysts, on average, expected it to report $3.04 per share.Its quarterly revenue doubled to $98.2 million and topped Wall Street’s estimate of $73.9 million.Sezzle’s gross merchandise volume, which denotes the total value of transactions on the platform, hit a new high of $855.4 million, aided by strong holiday season demand and the positive impact of its partnership with WebBank partnership.Through the partnership with WebBank, the company launched Sezzle On-Demand, which allowed non-Sezzle subscribers to use the platform for a one-time fee.The buy-now-pay-later company’s monthly on-demand and subscribers count rose to 707,000 from 307,000 in the year-ago quarter.The company’s active consumers rose 4.8% to 2.73 million during the fourth quarter.Sezzle raised its 2025 net income per share forecast to $13.25 from its earlier projection of $12.The company expects total revenue growth between 25% and 30% this year.Retail sentiment on Stocktwits jumped to ‘extremely bullish’ (88/100) territory from ‘bullish’(58/100) a day ago, while retail chatter rose to ‘extremely high.'<figure class="image"><img style="aspect-ratio:804/181;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SEZL_Feb_25_eabc283597.JPG" alt="SEZL’s Sentiment Meter and Message Volume as of 01:08 a.m. ET on Feb. 26, 2025 | Source: Stocktwits" width="804" height="181"><figcaption>SEZL’s Sentiment Meter and Message Volume as of 01:08 a.m. ET on Feb. 26, 2025 | Source: Stocktwits</figcaption></figure>One bullish investor hoped that the company would start paying dividends soon.<stembedurl>https://stocktwits.com/Lengen/message/605777462</stembedurl>In December, now-disbanded short-seller Hindenburg <a href="https://stocktwits.com/news-articles/markets/equity/sezzle-stock-tumbles-post-hindenburgs-short-report/cJaVDwdR1w">alleged</a> that Sezzle was borrowing expensive capital to make ‘extremely risky loans’ and that the platform was rapidly losing customers and merchants.Sezzle had denied the allegations and said they were ‘misleading and out of context.’Over the past year, <a href="https://stocktwits.com/symbol/SEZL">Sezzle stock</a> has grown more than sixfold.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/extra-space-storage-stock-rises-after-upbeat-q4-core-ffo/chdJG87RU0">Extra Space Storage Stock Rises After Upbeat Q4 Core FFO, Retail Sits On The Fence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Sezzle logo, a financial technology company is displayed on a smartphone screen and in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sezzle Stock Spikes In Extended Trading After Robust Q4 Earnings, Fuels Retail Frenzy

Its quarterly revenue doubled to $98.2 million and topped Wall Street’s estimate of $73.9 million.

Equity

Logility Supply Chain Solutions Inc.(LGTY) shares jumped 24.7% on Monday after Clearlake Capital-backed Aptean agreed to buy the company for $14.30 per share in an all-cash deal.The price represents a 27% premium to the Jan. 23 Logility closing share price.The deal, announced on Friday after the bell, is expected to close in the second quarter of 2025.“The Logility platform delivers a mission-critical suite of AI-powered supply chain planning solutions designed to address even the most complex requirements,” Aptean CEO TVN Reddy said.According to Stocktwits calculations, the purchase price represents an equity value of $481.6 million.Logility is headquartered in Atlanta and helps a wide range of businesses to optimize their inventory, improve demand forecasting, and streamline production planning.In December, activist investor 2717 Partners had urged Logility to consider strategic alternatives, including a potential sale, after calling it unsuitable for public markets.Lazard is serving as financial advisor to Logility, the company said.<a href="https://stocktwits.com/symbol/LGTY">Logility</a> had reported a net loss of $2 million during the fiscal second quarter in October.Retail chatter on Stocktwits remained in ‘bullish’ (68/100) territory, albeit with a higher score than Friday, while retail chatter rose to ‘extremely high.’<figure class="image"><img style="aspect-ratio:915/215;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LGTY_Jan_27_8721e26fc5.JPG" alt=" LGTY’s Sentiment Meter and Message Volume as of 12:57 p.m. ET on Jan. 27, 2025 | Source: Stocktwits" width="915" height="215"><figcaption>LGTY’s Sentiment Meter and Message Volume as of 12:57 p.m. ET on Jan. 27, 2025 | Source: Stocktwits</figcaption></figure>One user hailed it as a big win for shareholders.&nbsp;<stembedurl>https://stocktwits.com/8OO2428478/message/601647274</stembedurl>The stock has gained 33.4% over the past six months and risen 21.5% in the past twelve months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/middleby-stock-rises-after-strategic-review-plan-announcement-retail-turns-bullish/chbl2kfRYT">Middleby Stock Rises After Strategic Review Plan Announcement, Retail Turns Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An illustration of two hands coming together in a handshake. (Getty Images)

Logility Soars After Buyout Deal With Aptean, Retail Welcomes It With Open Arms

The companies said the price represents a 27% premium to the Jan. 23 Logility closing share price.

FDM
First Trust Exchange-Traded Fund III - First Trust Dow Jones Select Microcap Index Fund

Feed

News

Sentiment

Fundamentals

Info

Latest FDM News

FDMFirst Trust Exchange-Traded Fund III - First Trust Dow Jones Select Microcap Index Fund